title: [Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides Farinae Drops].
abstract: OBJECTIVE
  To evaluate the safety and efficacy of sublingual immunotherapy with 'Dermatophagoides Farinae Drops' in D. farinae allergic asthma and/or rhinitis patients.
  
  
  METHODS
  A 25-week double-blind, placebo-controlled, multi-centered trail was conducted in 278 children (aged 4 - 18 yr) with mite-induced asthma and/or rhinitis. Patients were randomly assigned to receive sublingual immunotherapy (SLIT) with 'Dermatophagoides Farinae Drops' (n = 139) or placebo (n = 139) for 25 weeks and the dosage and administration strictly followed the manufacturer's instructions. At the beginning of the 2nd, 3rd, 4th, 6th, 10th, 14th, 18th, 22nd week of the treatment, the patients were asked to accept follow-up visit, during the clinical trial all patients and parents were asked to keep a daily record of their asthma symptom scores, rescue medicine use, rhinitis symptom scores, morning and evening peak expiratory flow. Asthma symptom scores, reduction in use of rescue medicine, rhinitis symptom scores, lung function tests, skin sensitivity to mite, mite-specific immunoglobulin (Ig) E and IgG4, and quality of life and adverse effect were assessed during the study.
  
  
  RESULTS
  (1) Of the 278 children, 27 dropped out before the study completion. (2) After 25 weeks of treatment, the median variability of PEFR was -1.38 for SLIT group and -0.90 for the placebo (P < 0.05). (3) Besides, the mean variability of medicine score of asthma was -0.08 for SLIT group and 0.52 for the plcebo (P < 0.05). (4) The median variability of rhinitis symptom score was -1.96 for SLIT group and -1.03 for the placebo (P < 0.01). (5) The rescue medicine usage of SLIT reduced but did not show significant differences between SLIT and placebo. (6) After 25 weeks treatment, the increase of D. farinae specific IgE antibody of two groups were similar, while specific IgG4 increased significantly in SLIT compared to the patients in control one (P < 0.01); (7) No severe adverse events happened in the trial and the most-likely adverse events were mild asthma and local rash.
  
  
  CONCLUSIONS
  Dermatophagoides Farinae Drops is safe and effective in treating allergic asthma and atopic rhinitis.
authors.affiliation: Department of Pediatrics, Renji Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200001, China.
authors.forename: Lan-Fang
authors.initials: LF
authors.lastname: Cao
authors.forename: Quan
authors.initials: Q
authors.lastname: Lu
authors.forename: Hong-Liang
authors.initials: HL
authors.lastname: Gu
authors.forename: Yan-Ping
authors.initials: YP
authors.lastname: Chen
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Min
authors.initials: M
authors.lastname: Lu
authors.forename: Yao-Qin
authors.initials: YQ
authors.lastname: Qian
authors.forename: Lan
authors.initials: L
authors.lastname: Li
authors.forename: Yi-Ping
authors.initials: YP
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000818:Animals; D001249:Asthma / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D040001:Dermatophagoides farinae / Q000737:chemistry / Q000378:metabolism*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008925:Mites / Q000737:chemistry*; D012220:Rhinitis / Q000628:therapy*